606 related articles for article (PubMed ID: 27238212)
21. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
[TBL] [Abstract][Full Text] [Related]
22. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
23. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
Menyhárt O; Győrffy B
Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698
[TBL] [Abstract][Full Text] [Related]
24. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
25. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
26. The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases.
Wu T; Qu PR; Zhang S; Li SW; Zhang J; Wang B; Liu P; Li CD; Zhao F
Sci Rep; 2020 Jun; 10(1):9769. PubMed ID: 32555264
[TBL] [Abstract][Full Text] [Related]
27. Classifying the medulloblastoma: insights from morphology and molecular genetics.
Ellison D
Neuropathol Appl Neurobiol; 2002 Aug; 28(4):257-82. PubMed ID: 12175339
[TBL] [Abstract][Full Text] [Related]
28. Pathology, diagnostics, and classification of medulloblastoma.
Orr BA
Brain Pathol; 2020 May; 30(3):664-678. PubMed ID: 32239782
[TBL] [Abstract][Full Text] [Related]
29. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
30. Are molecular subgroups of medulloblastomas really prognostic?
Frappaz D; Faure-Conter C; Meyronet D; Levard-Bonneville A; Beuriat PA; Sunyach MP; Barritault M
Curr Opin Neurol; 2018 Dec; 31(6):747-751. PubMed ID: 30300240
[TBL] [Abstract][Full Text] [Related]
31. Medulloblastoma genomics in the modern molecular era.
Kumar R; Liu APY; Northcott PA
Brain Pathol; 2020 May; 30(3):679-690. PubMed ID: 31799776
[TBL] [Abstract][Full Text] [Related]
32. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
33. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
[TBL] [Abstract][Full Text] [Related]
34. Wnt activation as a therapeutic strategy in medulloblastoma.
Manoranjan B; Venugopal C; Bakhshinyan D; Adile AA; Richards L; Kameda-Smith MM; Whitley O; Dvorkin-Gheva A; Subapanditha M; Savage N; Tatari N; McKenna D; Bassey-Archibong B; Winegarden N; Hallett R; Provias JP; Yarascavitch B; Ajani O; Fleming A; Bader GD; Pugh TJ; Doble BW; Singh SK
Nat Commun; 2020 Aug; 11(1):4323. PubMed ID: 32859895
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
Archer TC; Mahoney EL; Pomeroy SL
Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
[TBL] [Abstract][Full Text] [Related]
36. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
38. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
39. [Medulloblastoma].
Kanemura Y
No Shinkei Geka; 2022 Jan; 50(1):73-90. PubMed ID: 35169088
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation Analysis.
Tauziède-Espariat A; Huybrechts S; Indersie E; Dufour C; Puget S; Chivet A; Roux A; Pagès M; Gareton A; Chrétien F; Lechapt E; Ayrault O; Varlet P
Am J Surg Pathol; 2021 Apr; 45(4):558-566. PubMed ID: 33323893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
